Mark J. Kwakkenbos

Mark J. Kwakkenbos

Auto-generated profile, based on publicly available information

Mark J. Kwakkenbos

AIMM Therapeutics, Academic Medical Center, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2009 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MKMark J Kwakkenbos
Mark J Kwakkenbos
SDSean A Diehl
Sean A Diehl
EYEtsuko Yasuda
Etsuko Yasuda
ABArjen Q Bakker
Arjen Q Bakker
CGCaroline M M van Geelen
Caroline M M van Geelen
TBTim Beaumont
Tim Beaumont
Kwakkenbos et al. describe an in vitro method to generate antibody-secreting B cell lines from human peripheral blood memory B cells by transducing them with retroviral vectors encoding Bcl-6 and Bcl-xL. The approach can be used to stably and simultaneously produce high levels of B cell receptor (BCR) on the cell surface and secreted immunoglobulins, useful for studying BCR signaling and producing antigen-specific antibodies. The B cell lymphoma-6 (Bcl-6) and Bcl-xL proteins are expressed in germinal center B cells and enable them to endure the proliferative and mutagenic environment of the germinal center. By introducing these genes into peripheral blood memory B cells and culturing these cells with two factors produced by follicular helper T cells, CD40 ligand (CD40L) and interleukin-21 (IL-21), we convert them to highly proliferating, cell surface B cell receptor (BCR)–positive, immunoglobulin-secreting B cells with features of germinal center B cells, including expression of activation-induced cytidine deaminase (AID). We generated cloned lines of B cells specific for respiratory syncytial virus and used these cells as a source of antibodies that effectively neutralized this virus in vivo. This method provides a new tool to study B cell biology and signal transduction through antigen-specific B cell receptors and for the rapid generation of high-affinity human monoclonal antibodies.

1 April 2008 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SDSean A Diehl
Sean A Diehl
HSHeike Schmidlin
Heike Schmidlin
MNMaho Nagasawa
Maho Nagasawa
SHSimon van Haren
Simon van Haren
MKMark J. Kwakkenbos
Mark J. Kwakkenbos
HSHergen Spits
Hergen Spits
STAT family members have been implicated in regulating the balance between B cell lymphoma (BCL)6 and B lymphocyte induced maturation protein (BLIMP)1 to control plasma cell differentiation. We previously showed that STAT5 induces BCL6 to block plasma cell differentiation and extend the life span of human B cells. The heterogeneity in STAT activation by cytokines and their effects on B cell differentiation prompted us to investigate the effect of STAT3 activation in plasma cell differentiation. First stimulation with IL-21, which promotes plasma cell differentiation, induced robust and prolonged STAT3 activation in primary human B cells. We then investigated effects of direct STAT3 activation on regulation of plasma cell genes, cellular phenotype, and Ig production. Activation of a tamoxifen-regulated STAT3-estrogen receptor fusion protein triggered BLIMP1 mRNA and protein up-regulation, plasma cell phenotypic features, and Ig secretion. When STAT3 was activated by IL-21 in B cells ectopically expressing BCL6, BLIMP1 was up-regulated, but only partial plasma cell differentiation was achieved. Lastly, through coexpression of BCL6 and STAT3-ER, we verified that STAT3 activation functionally mimicked IL-21 treatment and that STAT3-mediated BLIMP1 up-regulation occurred despite high BCL6 expression levels indicating that BCL6 is not the dominant repressor of BLIMP1. Thus, up-regulation of BLIMP1 alone is not sufficient for differentiation of primary human B cells into plasma cells; concomitant down-regulation of BCL6 is absolutely required for completion of the plasma cell differentiation program.

11 December 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RFRobert H. E. Friesen
Robert H. E. Friesen
PLPeter S. Lee
Peter S. Lee
ESEsther J. M. Stoop
Esther J. M. Stoop
RHRyan M. B. Hoffman
Ryan M. B. Hoffman
DEDamian C. Ekiert
Damian C. Ekiert
IWIan A. Wilson
Ian A. Wilson
Significance: The HA surface glycoprotein on influenza A viruses mediates viral entry into host cells. HA is highly variable and classified into 18 divergent subtypes, which cluster into two major phylogenetic groups. Antibody CR8043 has heterosubtypic neutralizing activity against group 2 viruses, including H3 viruses that currently circulate in humans. X-ray and EM structures of CR8043 Fab in complex with H3 HAs reveal that the antibody targets a conserved epitope on the HA stem. Compared with CR8020, the only other structurally characterized group 2 neutralizing antibody, CR8043 binds to HA with a different approach angle using different contact residues. The epitopes of both antibodies are very similar, which suggests that this conserved stem epitope has great potential for design of therapeutics and vaccines.

15 October 2003 in Blood
Verified
Journal Article
Closed access
PDF file
MSMartin Stacey
Martin Stacey
GCGin-Wen Chang
Gin-Wen Chang
JDJohn Q. Davies
John Q. Davies
MKMark J. Kwakkenbos
Mark J. Kwakkenbos
RSRalph D. Sanderson
Ralph D. Sanderson
HLHsi-Hsien Lin
Hsi-Hsien Lin
Using multivalent protein probes, an evolutionarily conserved endogenous ligand for EMR2, a human myeloid cell–restricted EGF-TM7 receptor, was identified on the surface of a number of adherent cell lines. In addition, in situ staining of the ligand has revealed specific in vivo patterns consistent with a connective tissue distribution. The interaction is conserved across species and mediated exclusively by the largest EMR2 isoform containing 5 epidermal growth factor (EGF)–like modules. Antibody-blocking studies subsequently revealed that the fourth EGF-like module constitutes the major ligand-binding site. The largest isoform of CD97, a related EGF-TM7 molecule containing an identical EGF-like module, also binds to the putative EMR2 ligand. Through the use of mutant Chinese hamster ovary (CHO) cell lines defective in glycosaminoglycans (GAGs) biosynthesis as well as the enzymatic removal of specific cell surface GAGs, the molecular identity of the EMR2 ligand was identified as chondroitin sulfate (CS). Thus, exogenous CS GAGs blocked the EMR2-ligand interaction in a dose-dependent manner. EMR2-CS interaction is Ca2+- and sulphation-dependent and results in cell attachment. This is the first report of a GAG ligand for the TM7 receptors extending the already vast repertoire of stimuli of the GPCR superfamily.

26 September 2007 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
JHJörg Hamann
Jörg Hamann
NKNathalie Koning
Nathalie Koning
WPWalter Pouwels
Walter Pouwels
LULaurien H. Ulfman
Laurien H. Ulfman
MEMarco van Eijk
Marco van Eijk
MKMark J. Kwakkenbos
Mark J. Kwakkenbos
The EGF‐TM7 F4/80 is a defining marker of murine macrophage populations. Applying flow cytometric analysis using the newly generated mAb A10, and quantitative real‐time PCR, we here report the surprising observation that the human ortholog of F4/80, EGF‐like module containing mucin‐like hormone receptor (EMR)1, is absent on mononuclear phagocytic cells including monocytes, macrophages, and myeloid dendritic cells. Unexpectedly, we found that EMR1 expression is restricted to eosinophilic granulocytes, where expression is overlapping with the eotaxin receptor CCR3 and the immunoglobulin‐like lectin Siglec‐8. Absence on other leukocytes, including basophils, implies that EMR1 is a highly specific marker for eosinophils in humans.

27 November 2003 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
MKMark J. Kwakkenbos
Mark J. Kwakkenbos
EKElse N. Kop
Else N. Kop
MSMartin Stacey
Martin Stacey
MMMourad Matmati
Mourad Matmati
SGSiamon Gordon
Siamon Gordon
JHJörg Hamann
Jörg Hamann